Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Impulse control disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Impulse-control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity – failure to resist a temptation, an urge, an impulse, or the inability to not speak on a thought. Many psychiatric disorders feature impulsivity, including substance-related disorders, behavioral addictions, attention deficit hyperactivity disorder, antisocial personality disorder, borderline personality disorder, conduct disorder and some mood disorders.
Novel methods
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.
Owner:INTRA CELLULAR THERAPIES INC
Combination Therapy
The present invention features a novel therapy for treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate compound (e.g., topiramate) or an anticonvulsive sulfonylurea compound (e.g. zonisamide).
Owner:VIVUS
Awareness enhancement and monitoring devices for the treatment of certain impulse control disorders
InactiveUS20070080812A1Minimize false alarmInhibition of activationSensorsPsychotechnic devicesTime informationReal-time clock
Apparatus for monitoring and discouraging trichotillomania and other unwanted behaviors includes a proximity detector, an event logger, and a user input facilitating event characterization. The proximity detector includes a sensor and an element associated with the arm, hand, finger, head or other user body part. The proximity detector is operative to generate an output signal in the event that the element has physically moved to within a predetermined distance relative to the sensor. The apparatus further includes a device operative to alert the user in response to the output signal generated by the proximity detector. Additional circuitry is provided enabling events to be examined and reviewed. Such circuitry would include a memory for storing information associated with alert events and an interface allowing the events to be examined and reviewed on a personal computer, for example. The provision of a real-time clock further enables date or time information to be stored in conjunction with an event. For additional insight into the events, an input may be provided allowing a user to characterize an event at the time of occurrence.
Owner:PERLMAN DAVID
Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
PendingUS20180092839A1Powder deliveryOrganic active ingredientsSubstance abuserImpulse control disorder
Provided herein are portable application devices and compositions for nasal and oral delivery of substances and compositions to treat overdose, addiction and / or behavioral disordered persons.
Owner:GOOBERMAN LANCE L
Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.
Owner:ELI LILLY & CO
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
InactiveUS20120115849A1Prevent relapseAvoid problemsBiocideNervous disorderPhosphodiesteraseImpulse control disorder
This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Owner:OMEROS CORP
Use of enantiomeric pure escitalopram
The present invention relates to the use of anatiomeric pure escitalopram and / or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment resistant" patients.
Owner:H LUNDBECK AS
Andrographis Paniculata Compositions and Methods for Treatment of Addictions
InactiveUS20140072662A1Reduce the possibilityEffective treatmentBiocideNervous disorderCannabisOpioid Agonist
Methods and compositions for the treatment or prevention of addictions and impulse control disorders using Andrographis paniculata, active substances contained therein and extracts thereof, alone or in combination with other therapeutic agents. The methods and compositions of the invention are useful in the treatment or prevention of addiction to substances, including alcohol, nicotine, marijuana, opioid agonists cocaine, and amphetamines, as well as impulse control disorders, including pathological gambling and pathological overeating.
Owner:OMEROS CORP
Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
ActiveUS20160074414A1Increase volumeFast deliveryHeterocyclic compound active ingredientsControl disordersImpulse control disorder
This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and / or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.
Owner:DEMERX
Impulse control disorder biological detection marker (Impulsins) and medical purpose of Impulsins
The invention provides an impulse control disorder biological detection marker (Impulsins) and a medical purpose of the Impulsins. The medical purpose belongs to application of an ATP enzyme ATP13A2 to preparation of a behavior and motion abnormality disease biological detection marker. The behavior and motion abnormality is caused by impulse control disorder and dyskinesia; and the amino acid sequence of ATP13A2 is shown as SEQ.No.1. The invention also provides application of sphingomyelin reduction and ceramide increase in blood due to APT enzyme ATP13A2 abnormality to preparation of an impulse control behavior and motion abnormality disease biological detection marker. The invention also provides application of a ceramide similar compound FTY720 or a sphingomyelinase inhibition compoundFluoxetine to preparation of medicine for treating impulse control behavior and motion abnormality diseases. Novel treatment medicine is provided for the behavior and motion abnormality diseases. Thetheoretical basis is provided for the clinic study of the behavior and motion abnormality diseases.
Owner:HANGZHOU DUANLI BIOTECH CO LTD
Treatment of addiction and impulse-control disorders using PDE7 inhibitors
ActiveUS9220715B2Avoid practicalAvoid prolonged useBiocideAnimal repellantsPhosphodiesteraseImpulse control disorder
Owner:OMEROS CORP
Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
PendingUS20200352917A1Organic active ingredientsDispersion deliverySubstance abuserImpulse control disorder
A method to treat carfentanyl overdose comprising administrating a pharmaceutical formulation in the form of liquid solution for spray administration by the nasal and / or buccal route containing naltrexone as active ingredient in amounts greater than 1%.
Owner:GOOBERMAN LANCE L
Methods and compositions for treating impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
InactiveUS20160038505A1Reduce controlRelieve symptomsBiocideAnimal repellantsPharmacyControl disorders
This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and / or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.
Owner:DEMERX
2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)
InactiveUS20170260185A1Good choiceUseful in treatmentNervous disorderOrganic chemistrySubstance abuserImpulse control disorder
The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.
![2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/68a634a7-23d1-4986-b3f4-d8b07a0017a5/US20170260185A1-20170914-C00001.png "2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)")
![2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/68a634a7-23d1-4986-b3f4-d8b07a0017a5/US20170260185A1-20170914-C00002.png "2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)")
![2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/68a634a7-23d1-4986-b3f4-d8b07a0017a5/US20170260185A1-20170914-C00003.png "2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (DAT) protein for the treatment of e.g. attention deficit disorder (ADD)")
Owner:CHRONOS THERAPEUTICS
Treatment of addiction and impulse-control disorders using PDE7 inhibitors
ActiveUS11207275B2Avoid practicalAvoid prolonged useNervous disorderHydroxy compound active ingredientsControl disordersImpulse control disorder
This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Owner:OMEROS CORP
Method of treatment
Owner:DAVIS PATRICIA C +4
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
ActiveUS20130267502A1Reduce the power requiredAvoid practicalBiocideAnimal repellantsPhosphodiesteraseImpulse control disorder
This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Owner:OMEROS CORP
Treatments for neurogenetic disorders, impulse control disorders, and wound healing
The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V.
Owner:NOVODERMIX INT
2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)
InactiveCN107001367AOrganic active ingredientsNervous disorderSubstance abuserImpulse control disorder
The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.
![2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b6fdd24-358e-4d3b-b170-d679916f0f4f/BDA0001275465780000061.png "2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)")
![2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b6fdd24-358e-4d3b-b170-d679916f0f4f/BDA0001275465780000101.png "2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)")
![2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b6fdd24-358e-4d3b-b170-d679916f0f4f/BDA0001275465780000111.png "2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)")
Owner:CHRONOS THERAPEUTICS
Treatment of impulsivity-related disorders
ActiveUS10653680B2Prevent relapseControl or treat impulsivity control disordersNervous disorderPharmaceutical delivery mechanismMood instabilityControl disorders
The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R1 and R2 are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer in the range of from 0 to 5; and n is an integer in the range of from 0 to 4. The compound can also be used to treat or control impulsivity control disorders in patients undergoing dopamine agonist treatment, for example in patients suffering from Parkinson's disease or ADFID.
Owner:OXFORD UNIV INNOVATION LTD
Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
ActiveUS9592239B2Increase volumeReduce controlBiocideAnimal repellantsControl disordersImpulse control disorder
This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and / or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.
Owner:DEMERX IB INC
Method of treatment
Owner:ASTRAZENECA AB
Treatment of impulsivity-related disorders
ActiveUS20190111029A1Prevent relapseControl or treat impulsivity control disordersNervous disorderPharmaceutical delivery mechanismDiseaseControl disorders
The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R1 and R2 are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer in the range of from 0 to 5; and n is an integer in the range of from 0 to 4. The compound can also be used to treat or control impulsivity control disorders in patients undergoing dopamine agonist treatment, for example in patients suffering from Parkinson's disease or ADFID.
Owner:OXFORD UNIV INNOVATION LTD
System and method for assessing impulse control disorder
InactiveUS10292635B2Less inhibitedMore automatedHealth-index calculationDrug and medicationsControl disordersImpulse control disorder
A method of assessing the likelihood that an individual has impulse control disorder. The individual is provided with an actuator, and instructed to actuate the actuator as an acknowledgement of when the individual has completed a reward task. Actuation of the actuator is monitored and recorded. An automated diagnosis of ICD is produced and output, wherein a greater degree of actuation of the actuator by the individual is taken to indicate a greater likelihood that the individual has impulse control disorder.
Owner:GLOBAL KINETICS PTY LTD
Treatment of impulse control disorders
The present disclosure provides methods and compositions for treating Impulse Control disorders including, for example, pathological gambling using α2-adrenergic agonists, β-adrenergic receptor antagonists, or both.
Owner:THE MCLEAN HOSPITAL CORP
System and Method for Assessing Impulse Control Disorder
InactiveUS20160022192A1Less inhibitedMore automatedHealth-index calculationDrug and medicationsControl disordersImpulse control disorder
A method of assessing the likelihood that an individual has impulse control disorder. The individual is provided with an actuator, and instructed to actuate the actuator as an acknowledgement of when the individual has completed a reward task. Actuation of the actuator is monitored and recorded. An automated diagnosis of ICD is produced and output, wherein a greater degree of actuation of the actuator by the individual is taken to indicate a greater likelihood that the individual has impulse control disorder.
Owner:GLOBAL KINETICS PTY LTD
Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
ActiveUS20220331299A1More efficaciousToxic reductionOrganic active ingredientsNervous disorderCompulsive disordersSubstance dependence
There is provided a compound of formula (I), wherein L1 to L3′, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/4019f449-a681-4976-9bcc-23a7432d44b5/US20220331299A1-C00001.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/4019f449-a681-4976-9bcc-23a7432d44b5/US20220331299A1-C00002.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/4019f449-a681-4976-9bcc-23a7432d44b5/US20220331299A1-C00003.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
Owner:CHRONOS THERAPEUTICS
Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
PendingCN111315734ALow toxicityProlong the action timeOrganic active ingredientsNervous disorderCompulsive disordersSubstance dependence
There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, whichcompounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/60a196d6-4461-4529-af42-c73137e1cb05/FDA0002476758810000011.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/60a196d6-4461-4529-af42-c73137e1cb05/FDA0002476758810000021.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
![Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/60a196d6-4461-4529-af42-c73137e1cb05/FDA0002476758810000251.png "Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists")
Owner:CHRONOS THERAPEUTICS
Treating impulse control disorders with catechol-o-methyl-transferase inhibitors
The invention provides methods for treating impulse control disorders in patients with catechol-o-methyl-transferase inhibitors. The invention also provides methods for treating patients with obsessive compulsive disorders and substance addictions with catechol-o-methyl-transferase inhibitors.
Owner:GRANT JON E
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com